MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ljungman, M.
Right arrow Articles by Paulsen, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ljungman, M.
Right arrow Articles by Paulsen, M. T.

Vol. 60, Issue 4, 785-789, October 2001

The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits RNA Synthesis and Triggers Nuclear Accumulation of p53 That Is Unmodified at Ser15 and Lys382

Mats Ljungman and Michelle T. Paulsen

Department of Radiation Oncology, Division of Cancer Biology, University of Michigan Comprehensive Cancer Center (M.L., M.T.P.), and Program in Cellular and Molecular Biology, University of Michigan Medical School (M.L.), Ann Arbor, Michigan,

Roscovitine has been shown to induce the accumulation of the tumor suppressor p53, to arrest cells in the G1 and G2/M phases of the cell cycle, and to induce apoptosis in human cells. Although these cellular effects of roscovitine are thought to be caused directly by its specific inhibition of cyclin-dependent kinases, other mechanisms may contribute as well. In this study, we investigated whether roscovitine interferes with transcription in human cells. We have previously shown that blockage of transcription is a trigger for the induction of p53 and apoptosis in human fibroblasts. Here we show that mRNA synthesis is suppressed significantly by roscovitine in human cells. Furthermore, our results suggest that the mechanism by which roscovitine inhibits RNA synthesis involves the inhibition of the phosphorylation of the carboxyl-terminal domain of RNA polymerase II. Cells treated with roscovitine at doses that affected transcription were found to accumulate p53 in the nucleus; curiously, however, the nuclear accumulation of p53 was not accompanied by modifications at either the Ser15 or Lys382 sites of p53. We conclude that roscovitine is a potent inhibitor of RNA synthesis and that this inhibition may be responsible for the accumulation of nuclear p53.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green
Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. F. Cheok, A. Dey, and D. P. Lane
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination
Mol. Cancer Res., November 1, 2007; 5(11): 1133 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Z. T. Ruiz-Cortes, S. Kimmins, L. Monaco, K. H. Burns, P. Sassone-Corsi, and B. D. Murphy
Estrogen Mediates Phosphorylation of Histone H3 in Ovarian Follicle and Mammary Epithelial Tumor Cells via the Mitotic Kinase, Aurora B
Mol. Endocrinol., December 1, 2005; 19(12): 2991 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Lacrima, A. Valentini, C. Lambertini, M. Taborelli, A. Rinaldi, E. Zucca, C. Catapano, F. Cavalli, A. Gianella-Borradori, D. E. MacCallum, et al.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Ann. Onc., July 1, 2005; 16(7): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1
Cancer Res., June 15, 2005; 65(12): 5399 - 5407.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
P. Coy, R. Romar, S. Ruiz, S. Canovas, J. Gadea, F. Garcia Vazquez, and C. Matas
Birth of piglets after transferring of in vitro-produced embryos pre-matured with R-roscovitine
Reproduction, June 1, 2005; 129(6): 747 - 755.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
P. Coy, R. Romar, R. R Payton, L. McCann, A. M Saxton, and J L. Edwards
Maintenance of meiotic arrest in bovine oocytes using the S-enantiomer of roscovitine: effects on maturation, fertilization and subsequent embryo development in vitro
Reproduction, January 1, 2005; 129(1): 19 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Wesierska-Gadek, M. Gueorguieva, and M. Horky
Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells
Mol. Cancer Ther., January 1, 2005; 4(1): 113 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Tan, X. Yang, A. Berman, S. Zhai, A. Sparreboom, A. L. Parr, C. Chow, J. S. Brahim, S. M. Steinberg, W. D. Figg, et al.
Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer
Clin. Cancer Res., August 1, 2004; 10(15): 5038 - 5047.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. Lane
p53 from pathway to therapy
Carcinogenesis, July 1, 2004; 25(7): 1077 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Whittaker, M. I. Walton, M. D. Garrett, and P. Workman
The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
Cancer Res., January 1, 2004; 64(1): 262 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. Yanamadala and M. Ljungman
Potential Role of MLH1 in the Induction of p53 and Apoptosis by Blocking Transcription on Damaged DNA Templates
Mol. Cancer Res., August 1, 2003; 1(10): 747 - 754.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. DeRyckere, D. L. Mann, and J. DeGregori
Characterization of Transcriptional Regulation During Negative Selection In Vivo
J. Immunol., July 15, 2003; 171(2): 802 - 811.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. Nguyen, B. Malgrange, I. Breuskin, L. Bettendorff, G. Moonen, S. Belachew, and J.-M. Rigo
Autocrine/Paracrine Activation of the GABAA Receptor Inhibits the Proliferation of Neurogenic Polysialylated Neural Cell Adhesion Molecule-Positive (PSA-NCAM+) Precursor Cells from Postnatal Striatum
J. Neurosci., April 15, 2003; 23(8): 3278 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Ma, W. D. Cress, and E. B. Haura
Flavopiridol-induced Apoptosis Is Mediated through Up-Regulation of E2F1 and Repression of Mcl-1
Mol. Cancer Ther., January 1, 2003; 2(1): 73 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Boudrez, M. Beullens, E. Waelkens, W. Stalmans, and M. Bollen
Phosphorylation-dependent Interaction between the Splicing Factors SAP155 and NIPP1
J. Biol. Chem., August 23, 2002; 277(35): 31834 - 31841.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics